

CURRENT REPORT

Report date: 09.07.2020

Name of issuing company: Antibiotice SA

Headquarters: Iași, str. Valea Lupului nr. 1, zip code 707410

<http://www.antibiotice.ro>

E-mail: relatiicuinvestitorii@antibiotice.ro

Telephone/fax no. : 0232 209000 / 0232 209633

Unique registration code in the Trade Register Office: RO1973096

No. in the Trade Register: J22/285/1991

Subscribed and paid-up capital: 67,133,804.00 RON

The regulated market trading the securities issued: Bucharest Stock Exchange

Number of shares: 671,338,040

Number of votes: 671,338,040

Main characteristics of the securities issued by the company: nominative shares, nominal value: 0.10 lei

Important event to report:

Antibiotice has entered the US and UK markets with new medicines for Covid-19

Amid the SARS-CoV-2 virus pandemic, while the hospital and pharmacy markets in Romania have substantially reduced their activity, Antibiotice has identified opportunities in the consumption of medicines by attending and winning tenders in the international markets, such as the US and UK.

In early July 2020, Antibiotice made the first deliveries of two injectable anti-infectives used in the treatment associated with Covid 19 for the hospitals in the Great Britain and the United States of America. These first deliveries are at the forefront of the contracts concluded with the authorities of these countries after winning the tenders organized by the British and American health systems. 2.5 million vials will be delivered by the end of 2020. Antibiotice is currently entered in the tenders for 2021, our company aiming to develop its projects in the long run.

“With a representative portfolio of antibiotics, cardiovasculars, anti-inflammatories and dermatologicals, we have succeeded in this difficult times for all of us, with many restrictions, to offer medicines associated with Covid -19 both in Romania and in the international markets. Deliveries were made primarily to cover the need for anti-infective medicines for Romanian patients, our first priority in the last 65 years” declared Delia Racoveanu, Marketing & International Sales Director.

Accessing the UK market is part of a larger project developed by Antibiotice in Europe involving the Scandinavian countries, Germany, Poland, Hungary and the Netherlands. Our company has been also present in the US market for more than 10 years. Our anti-infective portfolio sold in the American hospitals has been enriched with a new, high generation product for which there are few producers worldwide.

“The fact that Antibiotice has become one of the manufacturers accepted by health

systems from extremely regulated and competing countries such as those in the European Union, Asia and the USA is important to us, because it is a recognition of quality of our medicines and implicitly a recognition of the performance of the Romanian pharmaceutical industry” Mrs. Racoveanu pointed out.

For these new products to be delivered to the UK and US markets, we prepared the product registration files according to the rules and requirements applicable in these markets, obtained marketing authorizations, participated in tenders and identified partners to distribute them.

Antibiotice has already accessed other international health systems in Serbia, Vietnam and Republic of Moldova with this sterile injectable medicines.

CEO,
Ec. Ioan NANI

